Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of…
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of ICT01 doses in combination with pembrolizumabICT01…